Evaluation of antibody to double stranded DNA and antibody to single stranded DNA levels in relation to biochemical markers in cardiovascular disease patients
Paper Details
Evaluation of antibody to double stranded DNA and antibody to single stranded DNA levels in relation to biochemical markers in cardiovascular disease patients
Abstract
Cardiovascular diseases are major public health issues, with very high mortality rates. The evaluation of anti-DNA antibody levels in patients with cardiovascular diseases aims to explore potential links between these antibodies and biochemical markers associated with cardiovascular diseases. This study aims to evaluate the levels of anti-DNA antibodies and their relationship with biochemical parameters in patients with cardiovascular diseases. Relatively healthy donors (30) and patients with cardiovascular diseases (60) were selected to determine the levels of anti-DNA antibodies in plasma using the ELISA method. Biochemical indicators such as cholesterol levels, triglycerides, glucose, apolipoproteins (apoB), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and atherogenic index were measured using the automated biochemical analyzer. The results showed a dependency relationship between cardiovascular diseases, autoimmunity, and biochemical markers. The level of anti-DNA antibodies (ranging from 0.03 to 0.17 U) varied according to the different clinical forms of cardiovascular disease and exhibited correlations with certain biochemical markers. A relatively weak and negative linear relationship was observed between the atherogenic index and anti-DNA antibody levels in all patient groups. A direct dependency relationship was also recorded between anti-DNA antibody levels and high-density lipoprotein (HDL) levels (Rs = 0.13). The results showed a dependency relationship between anti- dsDNA antibody levels and glucose levels (Rs = 0.12). The correlation between anti-DNA antibody levels and these biochemical markers could provide a better understanding of the role of immune responses in cardiovascular diseases and pave the way for new diagnostic and therapeutic strategies.
Baigent C, Blackwell L, Emberson J. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681.
Bertsias G, Cervera R, Boumpas DT. 2012. Lupus érythémateux disséminé: Pathogenèse et caractéristiques cliniques. Manuel EULAR sur les maladies rhumatismales 5, 476–505.
Blatt NB, Glick GD. 1999. Anti-DNA autoantibodies and systemic lupus erythematosus. Pharmacology & Therapeutics 83, 125–139. https://doi.org/10.1016/S0163-7258(99)00022-4
Couderc R, Lefevre G, Fiessinger J-N. 2012. Value of biological markers in cardiovascular disease. Académie Nationale de Médecine.
Dima A, Caraiola S, Jurcut C, Nitescu D, Badea C, Jurcut R. 2015. Ostéoprotégérine – un lien possible entre les anticorps antiphospholipides et l’athérosclérose.
Dong Y, Zhang Y, Xia L, Wang P, Chen J, Xu M, Liu X, Xia Y. 2017. The deposition of anti-DNA IgG contributes to the development of cutaneous lupus erythematosus. Immunology Letters 191, 1–9. https://doi.org/10.1016/j.imlet.2017.09.003
DuBrock HM, AbouEzzeddine OF, Redfield MM. 2018. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. PLOS ONE 13, e0201836. https://doi.org/10.1371/journal.pone.0201836
Dudas SP, Chatterjee M, Tainsky MA. 2010. Usage of cancer associated autoantibodies in the detection of disease. Cancer Biomarkers 6, 257–270.
El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, Bernstein RM, Bruce IN. 2004. Systemic lupus erythematosus: An independent risk factor for endothelial dysfunction in women. Circulation 110, 399–404. https://doi.org/10.1161/01.CIR.0000136807.78534.50
Ferrario CM, Strawn WB. 2006. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. American Journal of Cardiology 98, 121–128. https://doi.org/10.1016/j.amjcard.2006.01.059
Goldsby RA, Kindt TJ, Osborn BA. 2003. Enzyme-linked immunosorbent assay. Immunology 5, 148–150.
Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin L, Stability Investigators. 2017. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: Experiences from the STABILITY trial. Journal of the American Heart Association 6, e005077. https://doi.org/10.1161/JAHA.116.005077
Houehanou Sonou YCN. 2015. Épidémiologie des facteurs de risque cardiovasculaire en population tropicale – Cas du Bénin. Thèse en Santé Publique, Université de Limoges / Université d’Abomey-Calavi.
Jaén RI, Val-Blasco A, Prieto P, Gil-Fernández M, Smani T, López-Sendón JL, Delgado C, Boscá L, Fernández-Velasco M. 2020. Innate immune receptors, key actors in cardiovascular diseases. JACC: Basic to Translational Science 5, 735–749. https://doi.org/10.1016/j.jacbts.2020.03.015
Kaptoge S, Seshasai SRK, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GDO, Jorgensen T, Danesh J. 2014. Inflammatory cytokines and risk of coronary heart disease: New prospective study and updated meta-analysis. European Heart Journal 35, 578–589. https://doi.org/10.1093/eurheartj/eht367
Kim SY, Yu M, Morin EE, Kang J, Kaplan MJ, Schwendeman A. 2020. High-density lipoprotein in lupus: Disease biomarkers and potential therapeutic strategy. Arthritis & Rheumatology 72, 20–30. https://doi.org/10.1002/art.41059
Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. 2020. Cardiovascular disease in systemic lupus erythematosus: Recent data on epidemiology, risk factors and prevention. Current Vascular Pharmacology 18, 549–565. https://doi.org/10.2174/1570161118666191227101636
Lv S, Zhang J, Wu J, Zheng X, Chu Y, Xiong S. 2005. Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancers patients and tumor-bearing mice. Immunology Letters 99, 217–227. https://doi.org/10.1016/j.imlet.2005.03.019
Mattina GF, Van Lieshout RJ, Steiner M. 2019. Inflammation, depression and cardiovascular disease in women: The role of the immune system across critical reproductive events. Therapeutic Advances in Cardiovascular Disease 13, 175394471985195. https://doi.org/10.1177/1753944719851950
Nadjioroum N-A, Goudra AT, Otchom BB, Ndifor F, Mberdoum NM. 2022. Étude des marqueurs biochimiques des risques de maladies cardiovasculaires chez les patients adultes au CHU-RN de N’Djamena en 2020. Journal of Applied Biosciences 176, 36–44.
Narang VK, Bowen J, Masarweh O, Burnette S, Valdez M, Moosavi L, Joolhar F, Win TT. 2022. Acute pericarditis leading to a diagnosis of SLE: A case series of 3 patients. Journal of Investigative Medicine High Impact Case Reports 10, 232470962210778. https://doi.org/10.1177/23247096221077832
Pisetsky DS, Lipsky PE. 2020. Nouvelles connaissances sur le rôle des anticorps antinucléaires dans le lupus érythémateux disséminé. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-020-0480-7
Rekvig OP. 2022. The anti-DNA antibodies: Their specificities for unique DNA structures and their unresolved clinical impact—A system criticism and a hypothesis. Frontiers in Immunology 12, 808008. https://doi.org/10.3389/fimmu.2021.808008
Sedkaoui F, Akli H. 2017. Étude de la contribution du lymphocyte B à l’immuno-pathologie du lupus érythémateux systémique. Doctoral dissertation, Université Mouloud Mammeri.
Soni SS, Ronco C, Pophale R, Bhansali AS, Nagarik AP, Barnela SR. 2012. Cardio-renal syndrome type 5: Epidemiology, pathophysiology, and treatment. Seminars in Nephrology 32(1), 49–56.
Svenungsson E, Gunnarsson I, Fei G-Z, Lundberg IE, Klareskog L, Frostegård J. 2003. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor α/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis & Rheumatism 48, 2533–2540. https://doi.org/10.1002/art.11264
Vodounon C, Chabi C, Skibo Y, Ezin V, Aikou N, Kotchoni S. 2014. Influence of the programmed cell death of lymphocytes on the immunity of patients with atopic bronchial asthma. Allergy, Asthma & Clinical Immunology 10, 14.
Vodounon CA. 2017. Abzymes in the diagnosis of bronchial asthma. American Journal of Biomedical Research 5, 35–38.
Vuilleumier N, Montecucco F, Hartley O. 2014. Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World Journal of Cardiology 6, 314–326.
Wang X, Xia Y. 2019. Anti-double stranded DNA antibodies: Origin, pathogenicity, and targeted therapies. Frontiers in Immunology 10, 1667. https://doi.org/10.3389/fimmu.2019.01667
World Health Organization. 2020. Les 10 principales causes de mortalité. WHO. https://www.who.int/fr/newsroom/fact-sheets/detail/the-top-10-causes-of-death
Wylie MA, Malemud CJ. 2013. Deregulation of apoptosis in arthritis by altered signal transduction. International Journal of Clinical Rheumatology 8(4), 483.
Yaniv G, Twig G, Shor DBA, Furer A, Sherer Y, Mozes O. 2015. A volcanic explosion of autoantibodies in systemic lupus erythematosus: A diversity of 180 different antibodies found in SLE patients. Autoimmunity Reviews 14(1), 75–79.
Cyrille A. Vodounon, Lilya A. Ganeeva, Sergey N. Abramov, Atindehou G. Dossou, Boris B. Legba, Yulia Valerevna skibo, Zinaida I. Abramova (2025), Evaluation of antibody to double stranded DNA and antibody to single stranded DNA levels in relation to biochemical markers in cardiovascular disease patients; IJBB, V20, N2, April, P1-9
https://innspub.net/evaluation-of-antibody-to-double-stranded-dna-and-antibody-to-single-stranded-dna-levels-in-relation-to-biochemical-markers-in-cardiovascular-disease-patients/
Copyright © 2025
By Authors and International
Network for Natural Sciences
(INNSPUB) https://innspub.net
This article is published under the terms of the
Creative Commons Attribution License 4.0